Navigation Links
Protein 'switch' suppresses skin cancer development
Date:9/8/2008

HOUSTON - The protein IKKalpha (IKKα) regulates the cell cycle of keratinocytes and plays a key role in keeping these specialized skin cells from becoming malignant, researchers at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of Cancer Cell.

"We have shown that IKKα acts as a sentry, monitoring and, when necessary, halting proliferation of these important cells. In the first mouse model of its kind, we also found that deleting IKKα spontaneously induced squamous cell carcinomas by activating the epidermal growth factor receptor pathway," said senior author Yinling Hu, Ph.D., assistant professor in M. D. Anderson's Department of Carcinogenesis at the Science Park - Research Division in Smithville, Texas. "These results provide new therapeutic targets for prevention of skin cancer."

Keratinocytes originate in the basal layer of the epidermis to replace skin cells at the surface that have been shed. As keratinocytes gradually move up through the skin layers, they differentiate and eventually form the top layer of the skin, which is composed of squamous cells. The cycle ends through terminal differentiation, in which cells lose their ability to reproduce by dividing in two. They eventually die.

Hu and colleagues reported in research last year that a reduction in IKKα expression promotes the development of chemically induced papillomas and carcinomas, which are benign and malignant tumors of the epithelium respectively. Epithelial cells make up the outer layers of skin and the inner linings of many organs, including the lungs and the gastrointestinal, reproductive and urinary tracts. Most cancers originate in organ epithelial cells. The researchers also demonstrated that an intact IKKα gene is required to suppress skin cancer development.

Downregulation of IKKα has been noted in a variety of human squamous cell carcinomas, including those of the skin, esophagus, lungs, and head and neck.

IKKα's role in maintaining skin homeostasis, or stability, had remained unclear because an appropriate mouse model was not available. To solve this problem, Bigang Liu, the first author, and colleagues generated mice with IKKα deletions in their keratinocytes.

In a series of experiments, Hu's group found evidence that IKKα functions as a sentry that monitors keratinocyte proliferation and then induces terminal differentiation. In one experiment, within a few days of birth, mutant mice had developed thickened and wrinkled skin and gradually showed retarded development. The researchers also found that even a low level of IKKα in the epidermis was sufficient to allow normal embryonic skin development.

The researchers examined the signaling pathways involved in overproliferation and reduced differentiation in IKKα -deficient cells. In one, they found that IKKα turns down a cellular signaling loop that activates EGFR and other growth factors previously found to regulate keratinocyte proliferation and differentiation.

Another experiment demonstrated that IKKα deletions in keratinocytes cause skin carcinomas and that inactivating EGFR reverses this process in the mutant mice. Furthermore, either inactivation of EGFR or reintroduction of IKKα inhibited excessive cell division, induced terminal differentiation, and prevented skin cancer by repressing the EGFR-driven signaling loop.

Hu's group concluded that IKKα is a switch for proliferation and differentiation and is essential to maintaining skin homeostasis, or stability, and preventing skin cancer.

"This study has revealed the importance of IKKα in maintaining skin homeostasis and in preventing skin cancer, as well as the mechanism of how IKKα acts in these processes," Hu said. "We will further investigate how IKKα deletion targets a single cancer initiation cell, which will provide new avenues to treat cancer."


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Scientists Track Hourly Changes in Alzheimers Protein
2. Computer-Based Method IDs Alzheimers Protein Structures
3. Bone Growth Protein Also Promotes Good Fat
4. Fat Cell Protein Boosts Heart Attack Risk in Elderly
5. Protein Key to Brain Rewiring
6. Recipe for cell reprogramming adds protein
7. Key to virulence protein entry into host cells discovered
8. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
9. Protein made by fat cells may increase risk of heart attack in older adults
10. Scientists ID Jekyll-Hyde Protein in Lou Gehrigs Disease
11. A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today announced that ... Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will be the ... patient signatures solution in healthcare . , Since it first introduced Electronic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow ... Tri-Conference February 20 – 22 in San Francisco. As part of the Tri-Conference ... molecular pathology workflow solution, as well as its new precision medicine platform, “Crosswalk ...
(Date:2/16/2017)... New York, New York (PRWEB) , ... February ... ... hard work and determination. After what took over 10 years of research, development ... disruptive technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
(Date:2/16/2017)... -- Prescription pain medications provided by "physicians in the months ... opioid use to take hold," according to a new ... The New England Journal of Medicine (NEJM). ... acute pain than in almost any other medical setting," ... the American College of Emergency Physicians. "The challenge is ...
(Date:2/16/2017)... Research and Markets has announced the addition of the "Global ... Cancer Type, Technology - Forecast to 2025" report to their ... The ... a CAGR of around 28.6% over the next decade to reach ... the prominent trends that the market is witnessing include increasing demand ...
Breaking Medicine Technology: